Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 20 de 1454 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Bateman BT. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine 2020;17:1 de septiembre. [Ref.ID 103726]
2. Cita con resumen
Blotière P-O, Miranda S, Weill A, Mikaeloff Y, Peyre H, Ramus F, Zureik M, Coste J, Dray-Spira R. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020;10:e034829. [Ref.ID 103654]
3. Cita con resumen
Zhu H, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Starub L, Huybrechts KF. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020;369:20 de mayo. [Ref.ID 103628]
4.Enlace a cita original Cita con resumen
Wen SW, Miao Q, Taljaard M, Lougheed J, Gaudet L, Davies M, Lanes A, Leader A, Corsi DL, Sprague AE, Walker M. Associations1 of assisted reproductive technology and twin pregnancy with risk of congenital heart defects. JAMA Pediatrics 2020:1. [Ref.ID 103549]
6. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
8. Cita con resumen
Blotière P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, Rouget F, Zureik M, Coste J, Dray-Spira R. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019;93:. [Ref.ID 103248]
9. Cita con resumen
Ji Y, Azuine RE, Zhang Y, Hou W, Hong X, Wang G, Riley A, Pearson C, Zuckerman B, Wang X. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2019:30 de octubre. [Ref.ID 103208]
10.Enlace a cita original Cita con resumen
Christensen J, Pedersen LH, Sun Y, Dreier JW, Brikell I, Dalsqaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2019;2:4 de enero. [Ref.ID 103010]
11.Enlace a cita original Cita con resumen
Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 2018:16 de agosto. [Ref.ID 102798]
12. Cita con resumen
Anónimo. Gadolinium, IRM et grossesse: des risques pour l'enfant à naître. Prescrire 2018;38:513-5. [Ref.ID 102762]
13. Cita con resumen
Viktorin A, Levine SZ, Altemus M, Reichenberg A, Sandin S. Paternal use of antidepressants and offspring outcomes in Sweden: nationwide prospective cohort study. BMJ 2018;361:k2233. [Ref.ID 102749]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;381:29 de agosto. [Ref.ID 102748]
15.Tiene citas relacionadas Cita con resumen
Rasmussen SA, Barfield W, Honein MA. Protecting mothers and babies — A delicate balancing act. N Engl J Med 2018:24 de julio. [Ref.ID 102747]
16. Cita con resumen
Anónimo. Valproato (Depakine / Depakine Crono): programa de prevención de embarazos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:24 de julio. [Ref.ID 102721]
17. Cita con resumen
Given JE, Loane M, Garne E, Addor M-C, Bakker M, Bertaut-Nativel B, Gatt M, Klungsoyr K, Lelong N, Morgan M, Neville AJ, Pierini A, Rißmann A, Dolk H. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ 2018;361:k2477. [Ref.ID 102696]
18.Enlace a cita originalTiene citas relacionadas
Kerr MP. Guidance is needed on valproate in pregnancy for those without capacity. BMJ 2018;361:29 de mayo. [Ref.ID 102684]
19.Enlace a cita originalTiene citas relacionadas Cita con resumen
Braillon A, Bewley S. Prescribing in pregnancy shows the weaknesses in pharmacovigilance. BMJ 2018;361:29 de mayo. [Ref.ID 102683]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]
Seleccionar todas
 
 1 a 20 de 1454 siguiente >>